The Relationship Between the Recognition of Basic Emotions and Negative Symptoms in Individuals With Schizophrenia Spectrum Disorders – An Exploratory Study

Marco Zierhut 1,2,*, Kerem Böge 1, Niklas Bergmann 1, Inge Hahne 1, Alice Braun 3, Julia Kraft 3, Thi Minh Tam Ta 1, Stephan Ripke 3, Malek Bajbouj 1 and Eric Hahn 1

1 Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2 BIH Charité Junior Clinician Scientist Program, BIH Biomedical Innovation Academy, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany, 3 Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, Berlin, Germany

Current research suggests that emotion recognition is impaired in individuals affected by schizophrenia spectrum disorders (SSD). However, the specific impact of negative symptoms on the ability to recognize single basic emotions has not yet been explored sufficiently and is the aim of the present study. A sample of \( N = 66 \) individuals diagnosed with SSD was recruited at the Charité – Universitätsmedizin Berlin. In a first step, correlation analyses were conducted between seven different negative symptom subdomains of the Positive and Negative Syndrome Scale (PANSS) and the accuracy and latency in recognizing the six basic emotions (anger, disgust, fear, happiness, sadness, surprise) using the Emotion Recognition Task (ERT) of the Cambridge Neuropsychological Test Automated Battery (CANTAB). The significant correlations were subjected to linear regression models that controlled for the significant covariates diagnoses, age, sex, and education. Results revealed that in individuals with SSD the negative symptom domain of blunted affect significantly predicted the accuracy of emotion recognition performance \( (p < 0.05) \), particularly, when recognizing happiness \( (p < 0.05) \). Additionally, we found that stereotyped thinking also predicted the performance of emotion recognition, especially the response latency \( (p < 0.05) \) and difficulty in abstract thinking predicted the recognition of fear \( (p < 0.05) \). However, the nominal significances did not withstand correction for multiple tests and therefore need to be followed up in further studies with a larger sample.

Keywords: schizophrenia spectrum disorders, negative symptoms, emotion recognition, schizophrenia, psychosis

INTRODUCTION

Social cognition is a crucial domain for interacting with other people and participation in society. It has been defined as the psychological processes that underlie social interactions, including perception, experience sharing, mentalizing, and experiencing and regulating emotion and information about other people and about ourselves \((1, 2)\). Among this heterogeneous category...
of processes, the most important domains of social cognition include the perception of social cues like emotion perception (1–4). Individuals affected by schizophrenia spectrum disorders (SSD) show significant impairments in their ability to recognize and express emotions, as already described by Kraepelin (2, 5, 6). Previously, studies of emotion deficits in schizophrenia focused on three main domains: expression, experience, and recognition of emotions. A review of 110 studies revealed marked impairment in all three domains in individuals with SSD (7). It is essential to differentiate between emotion recognition – which refers to the ability to recognize an expression of emotion such as disgust - and finding a face disgusting, which is called subjective appraisal (7). Emotion recognition has been linked to emotional intelligence and social perception, whereas appraisal has been linked to emotion processing (7). Gur et al. (8) reported an association of greater impairment for individuals with SSD in emotion recognition via facial stimuli with the severity of negative symptoms. Social cognitive impairments and negative symptoms are core features of SSD closely associated with high burden due to impairments in social functioning and quality of life already apparent prior to illness onset (2, 5, 6, 9–12). For example, attenuated impairment in emotion recognition manifests in unaffected first-degree relatives, ultra-high-risk individuals (13, 14), and young individuals with first-episode schizophrenia (5, 15, 16). A study found that young individuals with schizophrenia were impaired in their ability to recognize faces and gestures from movie scenes during the first two to 3 years of their illness after symptom onset (15, 17). According to Comparelli, Corigliano (13), facial emotion recognition impairment already present in ultra-high-risk individuals remained stable across the course of illness. Deficits in emotion recognition may be one of the most consistent and severe aspects of interpersonal problems (15) and impairment of social skills (18) and are related to poorer social outcomes in schizophrenia (19). Some researchers argue emotion recognition deficits are long-term stable features of schizophrenia (20). In one model, negative symptoms, emotion recognition latency, and processing speed were significant predictors of social functioning in individuals at ultra-high risk for psychosis (21, 22). Another model for schizophrenia onset included face emotion processing and negative symptoms as predictors of transition in individuals at high clinical risk to schizophrenia with an accuracy of 96% (11). Accordingly, this represents a particularly relevant field of research since both negative symptoms and impairments in social cognition could be apparent prior to illness onset with psychotic symptoms (10, 11).

Impaired emotional functioning has been linked to negative symptoms and can be conceptualized as a fundamental clinical feature in SSD (7, 23, 24). Newer discussions on deficits in emotion recognition raise the question of whether those belong to the negative symptom spectrum or form a separate domain in SSD (1, 25, 26). According to recent models, negative symptoms are also described as deficient social cognitions (27). The existing data non-ethéwise suggest that negative symptoms and social cognition are related, yet distinct constructs. Over time, deficits in social cognition could manifest behaviourally as negative symptoms (1). There are different models for a possible connection between social cognition and negative symptoms. On the one hand it is assumed that specific impairments in social cognition are linked to one or some negative symptoms but not others, which means there is a mechanistic heterogeneity. In support of this model, associations between only specific social cognition domains and negative symptoms have been reported (1). On the other hand, findings support broad impairments in basic sensory and cognitive processes (e.g., visual perception, motor output, processing speed, and implicit attention), which affect downstream processes. These are directly involved in social cognitive operations, which, in turn, result in the development of a range of negative symptoms and functional impairment (1). In studies looking at various factor models no correlations were found between the social cognitive factors and negative symptoms suggesting that social cognition and negative symptoms are largely separate constructs. They can be seen as relatively independent causes of dysfunction and disability and can be used to meaningfully classify non-acute patients (12, 28, 29). Furthermore, the entry level of negative symptoms was significantly associated with poor social functioning. Important predictive links have been found in the early course of schizophrenia, mostly indicating that higher negative symptom severity is associated with poor daily functioning and worse long-term outcomes (30–33). Given this, there is increasing interest in understanding to what amount negative symptoms reflect the expression of deficits in social cognition and the relationship between the two symptom domains (1). However, little is known about the dependence of these dimensions of illness and, whether individuals with schizophrenia can be meaningfully classified based on these dimensions and potentially differentially treated. Ruocco et al. (34), who compared emotion recognition deficits in individuals with schizophrenia, schizoaffective disorders, and bipolar disorders, discovered that compared to healthy controls, emotion recognition deficits among individuals increased progressively from bipolar disorder to schizoaffective disorder to schizophrenia. The researchers concluded that emotion recognition deficits are apparent at the first psychotic episode and prominent but different across psychotic disorders and relatively independent of mood state and antipsychotic treatment dosages (34–36). Conclusively illness-related characteristics like negative symptoms need further investigation (34–36). A priority of negative over positive symptoms in determining deficits in social cognition and functioning in chronic schizophrenia was concluded by many researchers (5, 37). To develop intervention approaches in the early phase of SSD, it is crucial to understand the longitudinal course of negative symptoms, especially in relationship to functioning (30).

There are, however, no sufficient treatment options for negative symptoms. The most often employed approaches as medication, psychotherapy, psychosocial interventions, and electroconvulsive therapy have only small effect sizes (38–40). A model of negative symptoms as the behavioral manifestation of altered social cognition has the potential to reveal areas of intact functioning, including domains of social cognition that remain unaffected by the illness, which novel treatments could rely upon to enhance the recovery of individuals with schizophrenia (1). The findings regarding social cognition in schizophrenia have treatment implications and the social processes that are
aberrant in schizophrenia may each require their own specific therapeutic intervention. Training programmes that target facial emotion perception and mentalizing deficits have been validated in individuals with schizophrenia (2, 41, 42).

Some researchers, such as Schneider et al. (43), concluded that especially impairments in facial emotion perception were strongly associated with the severity of negative symptoms. Since then, several studies have investigated the connection between negative symptoms and emotion deficits, but findings on the relationship between emotion recognition and negative symptoms remain inconclusive (5, 15, 43–56). There are various explanations for these mixed results. Most of the studies did not differentiate subdomains of negative symptoms and only considered negative symptoms overall. Also, some studies did not include all six basic emotions in their experimental designs but presented the subjects with a smaller selection of emotional stimuli. Paul Ekman first defined the six basic emotions: anger, disgust, fear, happiness, sadness and surprise (15, 57). Furthermore, different operationalizations and instruments for negative symptoms could be a source of variation (58, 59). To better understand the link between specific negative symptoms and emotion recognition, this study aims to explore the relationship between recognizing the six basic emotions and seven distinct negative symptoms in individuals with SSD in an exploratory approach by using the Positive and Negative Syndrome Scale (PANSS) (60) and the Emotion Recognition Test of the Cambridge Neuropsychological Test Automated Battery (ERT-CANTAB) (61).

According to the current state of research, five key subdomains of negative symptoms have been identified: (1) avolition, (2) anhedonia, (3) blunted affect (4) social withdrawal, and (5) alogia (9, 62–64). Negative symptoms can be assessed via various instruments [e.g., PANSS, Scale for the Assessment of Negative Symptoms (SANS) (65), Brief Negative Symptom Scale (BNSS) (66), Clinical Assessment Interview for Negative Symptoms (CAINS) (67), Negative Symptom Assessment (NSA) (68)]. So, it is necessary to consider the nature of each measurement instrument, especially with the aim of relating each symptom domain to the recognition of individual basic emotions. The domain of negative symptomatology is very complex encompassing primary and secondary symptoms as a result of medication side effects, depressive symptomatology and other causes (64). In SSD, studies confirmed moderate to large associations between negative symptoms and deficits in social cognition using the SANS (65) and/or the PANSS (1, 5, 12, 28, 30, 60, 69) as well as newer negative symptom scales like the BNSS (1, 5, 12, 66, 70). In many older studies, the negative syndrome scale of the classic PANSS was used to assess the individual domains of negative symptoms. However, according to recent factor analytic studies, it must be considered that the two symptom domains difficulty in abstract thinking (N5) and stereotyped thinking (N7) are now no longer regarded as negative symptoms but are assigned to the domain of cognitive symptoms (56) and difficulty in abstract thinking (N5) to the domain of disorganization, depending on the study design (71). This should therefore be considered when evaluating results using the PANSS. Nevertheless, in the context of an explorative approach of our study and for comparability with previous studies, especially older ones, we selected the PANSS as the primary rating tool for negative symptoms as a still frequently used third-party rating instrument in clinical studies (1, 5, 12, 28, 30, 60, 69). Depending on our results, a selection of the other measurement instruments should also be included in follow-up studies for an even better understanding of the relationships between negative symptoms and social cognition. We selected the Emotion Recognition Test of the CANTAB to measure the recognition of basic emotions. It contains all six basic emotions and is easy to use as a tablet-based measurement instrument in different settings (61). It is explicitly part of the Schizophrenia Test Battery of the CANTAB and several studies with patients with SSD have already been conducted with it. For example, Gica et al. (20) could show with the ERT-CANTAB, that emotion recognition deficits are long term stable features of schizophrenia and Kancharanatawet al. (72) showed associations of anxiety and depressive symptoms in individuals with SSD with social cognition by using the ERT-CANTAB. Glinthøj et al. (22) could show impairments in social cognition with the ERT-CANTAB in ultra-high risk for psychosis individuals and that hereby emotion recognition latency but not accuracy relates to real life functioning in these individuals (21).

MATERIALS AND METHODS
Sample and Procedure
The recruitment of participants was based on recommendations of a multiprofessional team. A sample of \( N = 66 \) individuals diagnosed with SSD was recruited at the in- \( n = 36 \) and out-patients \( n = 30 \) clinic of the Department for Psychiatry and Psychotherapy at the Charité – Universitätsmedizin Berlin, Germany (see Table 1). Of these, \( n = 54 \) were diagnosed with schizophrenia and \( n = 12 \) with a schizoaffective disorder. For inclusion, participants had to a) be aged between 18 to 65, b) meet diagnostic criteria for SSD (ICD-10: F2X.X) assessed by an attending psychiatrist and c) be able to give informed consent to participate in the study. Exclusion criteria encompassed (a) a score \( > 6 \) on any item of the positive scale of the Positive and Negative Syndrome Scale (PANSS) (60), which suggests an acute psychotic episode with severe psychotic symptoms, (b) acute suicidality assessed with the Clinical Decision Support System (CDSS) (item 8 > 1) (73), (c) current substance use other than nicotine or (d) the existence of neurological disorders or brain damages. For inpatients, the surveys were conducted within the first 8 weeks of treatment to avoid long hospitalization as a possible influencing factor on negative symptoms, respectively the exclusion criteria of an acute psychotic episode. The prescribed psychotropic medication and dosage was systematically recorded (see Table 2). Trained clinical staff assessed the seven different negative symptoms using the PANSS (60). The individuals’ ability to recognize the six basic emotions happiness, sadness, fear, anger, surprise and disgust was measured using the Emotion Recognition Task (ERT) of the Cambridge Neuropsychological Test Automated Battery (CANTAB) (61) on an Apple® iPad Air using the software iPadOS 15.2. Basic demographic information of the study sample is summarized in Table 1.
### Measures

#### The Positive and Negative Syndrome Scale (PANSS)

The Positive and Negative Syndrome Scale (PANSS) is a clinical instrument specifically designed to measure symptoms associated with SSD on a 7-point scale (1 = absent, 2 = minimal, 3 = mild, 4 = moderate, 5 = moderate severe, 6 = severe and 7 = extreme). It encompasses three subscales; seven items to measure positive symptoms, seven items for negative symptoms and 16 on general symptomatology (60). Furthermore, the scale allows the calculation of a global score of overall symptom severity. These items are rated based on a comprehensive interview carried out by a trained clinician. The Negative Scale of the PANSS was used to assess the seven itemized negative symptoms: blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive and apathetic social withdrawal (N4), difficulty in abstract thinking (N5), lack of spontaneity and flow of conversation (N6) and stereotyped thinking (N7). Regarding the psychometric properties of the Negative Scales of the PANSS, it can be said that the PANSS scores are normally distributed, and negative scales showed good interrater reliability. Negative syndromes also proved their factorial validity. The Negative Scale also held a high concurrent validity with the Scale for the Assessment of Negative Symptoms (SANS) (60, 65, 74).

#### Emotion Recognition Task (ERT)

The assessment of emotion recognition was carried out with the iPad version of the validated Cambridge Neuropsychological Test Automated Battery (CANTAB) in German language. The CANTAB is a computerized assessment developed from animal behavior paradigms and human neuropsychology, initially developed in the late 1980s (61). It has been widely used in many neurocognitive examinations of individuals with and without SSD (75). The largely non-verbal nature of the tests makes the CANTAB practical for use across multisite and multilingual clinical trials. The CANTAB schizophrenia test battery comprises computerized neuropsychological tests presented on a touchscreen system assessing eight cognitive domains most impaired in people affected by SSD. These captured cognitive domains were prioritized by the National Institute of Mental Health (NIMH) sponsored Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program (76). To assess social cognition within this study, we used the tablet-based Emotion Recognition Task (ERT), a facial emotion labeling task recently added to the battery, including testing for all six basic emotions: anger, disgust, fear, happiness, sadness, and surprise. Within this task participants are presented with computer-morphed faces expressing one specific emotion out of six basic emotions. Each face image is shown for 200 ms. The study participants are then asked to indicate the displayed emotion out of the six primary emotions or choose a neutral option. The task takes around 12 min to complete (61). Key outcome measures of the ERT are the overall median reaction time to select an emotion (ERTOMDRT), the unbiased hit rate for each of the six emotions: anger (ERTUHRA), disgust (ERTUHRD), fear (ERTUHRF), happiness (ERTUHRH), sadness (ERTUHRS) and surprise (ERTUHRSU).

### Ethical Approval

The current study was reviewed and approved by the Ethics Committee of Charité – Universitätsmedizin Berlin (EA4/225/19). All participants provided written informed consent to participate in this study.

### Statistical Analysis

The statistical analysis was carried out in R Studio Version 1.2.5033 running R version 4.0.4 and IBM SPSS Version 25. The following steps were performed for the statistical analyses in an exploratory approach of the study:

1. The Pearson’s correlation coefficient was calculated between the seven negative symptoms and the accuracy and latency of recognition for each basic emotion.

2. Multiple linear regression models followed up the significant correlations to investigate the relationship while controlling for the covariates diagnoses, age, sex, and education. For covariate analysis, multiple linear regressions were run to examine the effect of each potential covariate on each CANTAB variable.

3. Each significant correlation between a negative symptom and a CANTAB variable was tested as a linear regression model by including the significant covariates in the regression models.

4. Bonferroni corrections for multiple testing were performed despite a not sufficient sample size for statistical completeness. The Bonferroni adjusted p-value is reported as $p_{\text{Bonf}}$ respectively (77). Power and sample size calculations followed.

| TABLE 1 | F2-Diagnoses and demographic data of the sample. |
|----------|-----------------------------------------------|
| Variable | Overall, N = 66 | Schizophrenia Disorder (F25), n = 12 | Schizophrenia (F20), n = 54 |
| Sex      |                  |                                   |                               |
| Female   | 25 (38%)         | 8 (67%)                           | 17 (31%)                       |
| Male     | 41 (62%)         | 4 (33%)                           | 37 (69%)                       |
| Age      |                  |                                   |                               |
| N        | 66               | 12                                | 54                             |
| Mean (SD)| 41 (13)          | 50 (14)                           | 40 (12)                        |
| Range    | 19, 69           | 26, 69                            | 19, 67                         |
| Education|                  |                                   |                               |
| Gymnasium (ISCED 3) | 30 (46%)     | 6 (50%)                           | 24 (45%)                       |
| Realschule (ISCED 2) | 22 (34%)     | 5 (42%)                           | 17 (32%)                       |
| Hauptschule (ISCED 2) | 13 (20%)    | 1 (8.3%)                          | 12 (23)                        |
| Missing  | 1                | 0                                 | 1                              |

N, sample size; SD, Standard Deviation; ISCED, International standard classification of education.

[1] Zierhut et al. Emotion Recognition and Negative Symptoms
TABLE 2 | Overview of the antipsychotics taken during the study.

| Medication            | Generation / potency | Mean (SD) (mg) | Administration | Number of patients |
|-----------------------|----------------------|----------------|----------------|--------------------|
| Flupentixol           | FG / HP              | 4.7 (3.1)      | p.o.           | 3                  |
| Haloperidol           | FG / HP              | 3              | p.o.           | 1                  |
| Meliperone            | FG / LP              | 75             | p.o.           | 1                  |
| Pipamperone           | FG / LP              | 43.3 (29.4)    | p.o.           | 6                  |
| Aripiprazole          | SG                   | 13.4 (8.3)     | p.o.           | 13                 |
| Aripiprazole          | SG                   | 300            | i.m.           | 1                  |
| Cariprazine           | SG                   | 3 (0)          | p.o.           | 2                  |
| Clozapine             | SG                   | 266 (239)      | p.o.           | 22                 |
| Olanzapine            | SG                   | 19 (8.1)       | p.o.           | 11                 |
| Paliperidone          | SG                   | 5.3 (4.5)      | p.o.           | 5                  |
| Paliperidone          | SG                   | 112.5 (25)     | i.m.           | 4                  |
| Quetiapine            | SG                   | 240 (176.1)    | p.o.           | 10                 |
| Risperidone           | SG                   | 3.2 (1.2)      | p.o.           | 12                 |
| Risperidone           | SG                   | 37.5           | i.m.           | 1                  |
| Ziprasidone           | SG                   | 50 (42.4)      | p.o.           | 2                  |

FG, First Generation; SG, Second generation; HP, High potency; LP, Low potency; mg, milligram; p.o., per os; i.m., intramuscular.

RESULTS

In Figure 1, a correlational matrix with an overview of the findings that emerged after data collection is presented. Positive correlations within the respective scales can also be found in the literature (60, 78–80). There was a significant negative correlation between blunted affect (N1) and the total number of correct responses in emotion selection (r = −0.291, p < 0.05), the recognition of happiness (r = −0.349, p < 0.05), fear (r = −0.296, p < 0.05) and disgust (r = −0.291, p < 0.05). A significant negative correlation of difficulties in abstract thinking (N5) with fear recognition (r = −0.337, p < 0.05) was found. There was also a significant positive correlation of the response latency in emotion recognition with difficulties in abstract thinking (N5) (r = 0.289, p < 0.05) and stereotyped thinking (N7) (r = 0.349, p < 0.05). There were no significant correlations between the negative symptom domains emotional withdrawal (N2), poor rapport (N3), passive and apathetic social withdrawal (N4), and lack of spontaneity and flow of conversation (N6) and the assessed CANTAB variables among those with SSD. In the next step, linear regressions were run to examine a significant effect of the covariates age, education, sex and diagnoses on each CANTAB variable.

When controlling for age and education, a multiple linear regression analysis was conducted to assess whether blunted affect (N1) significantly predicted the total number of correct responses in emotion selection. Hereby blunted affect (N1) significantly predicted the total number of correct responses in emotion selection [B = −0.919, t = −2.199, p = 0.032]. Blunted affect (N1) could also be identified as a significant predictor of the accurate recognition of happiness when controlling for the covariates [B = −0.241, t = −2.113, p = 0.039]. Likewise, the negative symptom domain of difficulties in abstract thinking (N5) was identified as a significant predictor of fear recognition in the regression analyses [B = −0.037, t = −2.044, p = 0.045] when controlling for education. A linear regression analysis was conducted to assess whether difficulties in abstract thinking (N5) and stereotyped thinking (N7) predicted the response latency when controlling for age. In this model stereotyped thinking (N7) significantly predicted the response latency [B = 195.921, t = 2.400, p = 0.019], whereas the negative symptom difficulties in abstract thinking (N5) was not a significant predictor in this model [B = 117.474, t = 1.535, p = 0.130]. Linear regression analysis models showed that that blunted affect (N1) was not a significant predictor for recognizing either fear [B = −0.023, t = −1.699, p = 0.094], while controlling for the significant covariate education. For an overview of the above significant regression analyses, please refer to Table 3. The complete respective regression tables are provided in the Supplementary Material.

The demonstrated nominal significances did not withstand correction for 111 multiple tests. After Bonferroni correction, none of the mentioned correlation and regression analyses between PANSS and the ERT items, respectively, reached statistical significance (see Supplementary Material). With a power of 0.8, an expected small effect of $f^2 = 0.054$ of the PANSS negative scales on emotion recognition based on preliminary studies (81), and a $p$-value of 0.00045 corrected for 111 multiple tests, a sample size of 446 subjects would be necessary to detect a significant effect. According to the guidelines of Cohen (82) $f^2 \geq 0.02, f^2 \geq 0.15$, and $f^2 \geq 0.35$ represent small, medium, and large effect sizes, respectively.

DISCUSSION

Summary of the Main Results

In the present study, blunted affect (N1) emerged as the negative symptom most strongly predicting the total number
of correct responses, especially happiness recognition. First, a significant correlation was shown between blunted affect (N1) and happiness, fear and disgust. After controlling for the significant covariates, blunted affect (N1) only significantly predicted the recognition of happiness. We also found a prediction of difficulties in abstract thinking (N5) for recognizing the basic emotion of fear. Additionally, a significant correlation between difficulties in abstract thinking (N5) and response latency and a significant prediction of stereotyped thinking (N7) for the response latency in emotion recognition was found. However, results must be weighed against the methodological limitations of the study.

**Prediction for Response Latency in Emotion Recognition**

With reference to the results regarding response latency and the association with stereotyped thinking (N7) and difficulty in abstract thinking (N5), some authors assign stereotyped thinking, difficulties in abstract thinking alongside conceptual disorganization, disorientation, and poor attention rather to a cognitive symptom dimension than to the negative symptom dimension (56). This could explain the prediction for the response latency, where cognitive processing of impressions may play a role. Glenthøj et al. (21), also using the CANTAB for emotion recognition, reported that latency in emotion recognition, but not accuracy, related to real-life functioning for individuals at ultra-high risk for psychosis (21). More studies have been conducted on the relationship between cognitive capabilities and the ability to recognize emotions in individuals with SSD, but again with inconclusive results. According to Turetsky et al. (83), emotion recognition deficits could be assumed to be secondary to problems in a structural encoding of faces, and a specific signal recognition could play a role that precedes emotion recognition. Additionally, several studies reported a clear association between neuropsychological functions and emotion recognition (43, 56, 84, 85).
Prediction for the Correct Recognition of the Six Emotions

Blunted affect (N1) significantly predicted the recognition of happiness. The current study results have been confirmed in the literature, while other studies reported inconclusive results and need further classification (15). On the one hand, some authors like Turetsky et al. (83) showed that recognizing happy faces correlated with the severity of negative symptoms, especially in individuals with SSD. On the other hand, ratings in the blunted affect's subdomain uniquely predicted performance on the emotion processing tasks. They were associated with better speed and accuracy than other negative symptom domains (8). Blunted affect being more evident in men than women is in line with the findings of Kohler et al. (84), showing a poorer performance of men in emotion recognition. Several studies examined the relationship between impaired emotion perception with different symptom rating scales, e.g., the Brief Psychiatric Rating Scale (BPRS) (86), the Scale for the Assessment of the Positive Symptoms (SAPS) (87), the SANS (65), and the PANSS (60). Their impact and differences in the sample recruitment may have contributed to the inconsistencies reported in the literature (44) and should be further pursued. Since emotional impairments are connected to negative symptoms such as blunted affect and influence the course of illness from the onset on (8, 23, 55, 88), it would be important to focus on emotion recognition and early detection, especially regarding young individuals with SSD.

In some studies, the impaired recognition of positive emotions was found to be a prominent deficit in individuals with schizophrenia (34, 89) and significant group differences between individuals with SSD and healthy individuals were only limited to positive emotions like happiness (55, 56, 84). Tsoi et al. (89) showed that recognizing happy faces was more impaired than recognizing sad or fearful faces in a sample with individuals with schizophrenia. It could be shown that the perception of happy and sad emotions also relates differently to significant illness parameters such as age, intelligence quotient (IQ), cumulated time in hospital and negative symptoms (7, 48, 90). This supports the idea of the existence of an emotion-specific deficit in the perception of emotions in individuals with schizophrenia and of at least two separate neurobiological pathways for processing positive and negative emotions (18, 48, 89, 91–95).

The inconsistencies of the findings on differential abilities to recognize positive vs. negative affect states could also be due to methodological, stimuli and sampling differences or other as yet unknown variables (18, 56).

Implications for Future Research and Future Practice

Despite the needs and hopes for therapeutic interventions in the field of emotion recognition for individuals with SSD, many aspects in this field of research must be further clarified in future studies. Finally, a study design with a larger sample to follow up on the investigated predictors within the framework of our exploratory study would be helpful. This study initially pursued an exploratory approach to shed more light on the associations between negative symptoms and emotion recognition. Each significant correlation between a negative symptom and a CANTAB variable was tested as a linear regression model by including the significant covariates in the regression models. The nominal significances of our exploratory study did not withstand Bonferroni correction for multiple tests, which was performed despite a not sufficient sample size for statistical completeness in the exploratory approach. Nevertheless, this exploratory approach yielded results that can be built upon in follow-up studies with larger sample sizes, additional measurement instruments, and covariates. The correlation matrix (see Figure 1) shows significant within-correlations of all negative symptoms, some of which remain significant even after Bonferroni correction (see Supplementary Material). Therefore, the question arises whether the individual negative symptoms can even independently predict the ERT variables. Also, a larger sample could be used to calculate additional regression models in which all negative symptoms are included in future studies.

For covariate analysis, multiple linear regressions were run to examine the effect of each potential covariate on each CANTAB variable in our sample. Due to the initially exploratory approach of our study with a small sample size, the analyses were initially performed with a limited and selected number of covariates to control for. The variables that were expected to be most informative in the context of the study were diagnosis, gender, age, and education, as these include biological and cognitive components. The antipsychotic medication of the patients was systematically recorded and can be seen in Table 2. Due to the exploratory approach of our study with a small sample and the heterogeneity in medication, we did not statistically control for these. Since it could be

| TABLE 3 | Regression analysis predicting the ERT items resulting from the correlation analyses. |
|-----------------|---------------------------------|---------------------------------|----------------|----------------|----------------|
| Independent Variable | Unstandardized coefficient | Standardized coefficient | t | p | P<.01 |
| N1 | −0.919 | 0.417 | −0.241 | −2.199 | 0.032 | 1.000 |
| N1 | −0.034 | 0.016 | −0.241 | −2.113 | 0.039 | 1.000 |
| N5 | −0.037 | 0.018 | −0.270 | −2.044 | 0.045 | 1.000 |
| N7 | 195.921 | 81.634 | 0.287 | 2.400 | 0.019 | 1.000 |

Constant = 555.393, F(3, 62) = 6.402, p = 0.001, R² = 0.200; P<.01. Bonferroni adjusted p-value; N1, blunted affect; N5, difficulty in abstract thinking; N7, stereotyped thinking; ERTTH, the total number of correct responses; ERTUHRF, the unbiased hit rate for the emotion happiness; ERTUHFF, the unbiased hit rate for the emotion fear; ERTOMDRT, the overall median reaction time to select an emotion.
shown that emotion recognition is relatively independent of the influence of antipsychotics (34–36) and most antipsychotics of our sample belonged to second generation antipsychotics with only a minor influence on negative symptoms and cognitive functions (96), medication was considered as a negligible influence factor concerning the sample size. However, the heterogeneity of the collected medication in our sample reflects the treatment of patients with SSD for generalizability of the results. To allow generalizability of our study sample in this exploratory approach, we wanted to recruit as heterogeneous a cohort as possible, which also reflects a realistic representation of individuals with SSD in the inpatient and outpatient setting. In a large-scale follow-up study based on our results, further covariates like neurocognition, positive symptoms, medication and duration of illness and hospitalization should be therefore considered. A distinction between individuals with schizophrenia, schizoaffective disorders, and other diagnoses of SSD especially according to the ICD-11 classification regarding emotion recognition would be also of interest for future research in a larger sample. To reach the potential of personalized medicine, associations with the severity of predominant symptom manifestations should also be further illuminated in the framework of larger samples (34).

Additionally different measurements for negative symptoms are needed to ensure comparability. We initially chose the PANSS as the primary rating tool for negative symptoms within the framework of an explorative approach for the purpose of comparability with previous studies, especially older studies and due to inconsistencies in literature. The PANSS is a still frequently used external rating instrument in clinical studies. However, the limitations of the PANSS with respect to the nature of the negative symptom domains must certainly be considered in the interpretation of the results. Thus, as already mentioned, in factor analyses difficulty in abstract thinking (N5) and stereotyped thinking (N7) are attributed to the cognitive symptom domain (56) and difficulty in abstract thinking (N5) can be also accounted to the domain of disorganization (71). New generation scales like BNSS, CAINS and NSA should be included in follow-up studies to assess negative symptoms for an even broader understanding of their relationships with social cognition. Since most of the scales evaluate the behavioral side of negative symptoms, while the emotion recognition tasks assess the subjective experience, the new Self-evaluation of Negative Symptoms (SNS) (97) as a self-rating instrument would be an option for an additional perspective. Another alternative measure to be included is the recently introduced PANSS Autism Severity Score (PAUSS) (98, 99). The PAUSS is a score obtained from – essentially – the negative scale of the PANSS aimed to resemble autism spectrum disorder features in people with schizophrenia. It is a new construct with respect to autism conceptualized by classical continental psychopathology, as in the Autism Rating Scale (ARS) (100) and has already been studied in relation to social cognition (98).

Another reason for using the PANSS for our study was the ERT-CANTAB as an already relatively new measurement instrument to be chosen to capture emotion recognition. Hereby an advantage is the feasibility on a tablet and the thereby simple manageability. In addition, in studies by Glenthoj et al. (21) ERT-CANTAB was used in UHR for psychosis, so that in follow-up studies these individuals could be also included regarding the fact that impairments in emotion recognition and negative symptoms can already be determined before the onset of other symptoms (10, 11). However, different survey instruments for emotion recognition should be considered in follow-up studies to obtain a better insight independent of the measurement instrument. A comparison should therefore be made with likewise established measurement instruments for emotion recognition such as the Facial Emotion Identification Test (FEIT) (95), the Bell-Lysaker Emotion Recognition Task (BLERT) (101) or The Awareness of Social Inference Test (TASIT) (102). A systematic comparison of the measurement instruments would be of great benefit for clarifying the inconclusive results in literature. Research should be also expanded on all modalities of emotion recognition impaired in individuals with SSD (7, 15), including visual, verbal, and auditory channels (15). In addition, a longitudinal study and a study design for causality statements would be useful.

Consequently, impairments identified in the subdomains of negative symptoms and emotion recognition should be considered for early detection and individualized treatment as one of the research goals in social cognition in individuals with SSD, considering the enormous social burden. For example, specific interaction and emotion recognition training for a subgroup of individuals with specific profiles of negative symptoms, for instance in analogy to training programs for individuals with autism spectrum disorders (103, 104), could be developed to improve the recovery of individuals with SSD. Another treatment option that should be examined more closely in this area is the use of the neuropeptide oxytocin. In some studies, nasal oxytocin administration could improve the social performance of individuals with SSD (105).

**Strength and Limitations**

Concerning the size and selection of our exploratory study sample, larger diverse samples are needed to allow more precise analyses regarding the different variables. Our sample size calculations showed a sample size of 446 subjects required to detect a significant effect after correction for multiple testing. As could be expected, the nominal significances of our exploratory study did not withstand correction for multiple tests. Therefore, follow-up studies are necessary and recruitment for the present study is continued. Our research focused on negative symptoms, so we did not include positive symptom scores or total PANSS scores as well as further covariates like neurocognition. Only the CANTAB was used as a measurement instrument for emotion recognition. No comparison was made with other measurement instruments so that individual characteristics of the battery could have influenced the results. Additionally, different measurements for negative symptoms are needed to avoid bias and ensure comparability. Our results were collected in a cross-sectional design, so statements are limited to significant predictors in emotion recognition.
CONCLUSION

Conclusively in our exploratory study individuals with SSD and high scores of the negative symptoms showed impairments in recognizing basic emotions and, here, particularly happiness. However, results must be weighed against the methodological limitations of the study and follow-up studies are necessary.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Charité's Ethics Committee. The studies involving human participants were reviewed and approved by the Ethics Committee of the University Hospital Charité-Universitätsmedizin Berlin and the University of Zürich. In addition, the study was funded through the internal performance-based funding (LoM) of our research group at Charité – Universitätsmedizin Berlin.

REFERENCES

1. Pelletier-Baldelli A, Holt D. Are negative symptoms merely the "real world" consequences of deficits in social cognition? Schizophr Bull. (2019) 46:236–41. doi: 10.1093/schbul/sby095
2. Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. (2015) 16:620–31. doi: 10.1038/nrn4005
3. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. (2009) 195:475–82. doi: 10.1192/bjp.bp.108.055731
4. Gold J, Green M, Sadock B, Sadock V. Comprehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams & Wilkins (2004).
5. Andrzejewska M, Wójciak P, Domowicz K, Rybakowski J. Emotion recognition and theory of mind in chronic schizophrenia: association with negative symptoms. Arch Psychiatry Psychother. (2017) 19:7–12. doi: 10.12740/APP/7987
6. Kraepelin E. Dementia Praecox and Paraphrenia (R. Mary Barclay, Trans.). Edinburgh: Livingstone (1919).
7. Trémeau F, A. review of emotion deficits in schizophrenia. Dialogues Clin Neurosci. (2006) 8:59. doi: 10.31887/DCNS.2006.8.1/tremeau
8. Gur RE, Kohler CG, Ragland JD, Siegel SJ, Lesko K, Bilker WB, et al. Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull. (2006) 32:279–87. doi: 10.1093/schbul/sbj041
9. Marder SR, Galdersi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. (2017) 16:14–24. doi: 10.1002/wps.20385
10. Yung AR, Nelson B, McGorry PD, Wood SJ, Lin A. Persistent negative symptoms in individuals at ultra high risk for psychosis. Schizophr Res. (2019) 206:355–61. doi: 10.1016/j.schres.2018.10.019
11. Corcoran C, Keilp J, Kayser J, Klim C, Butler P, Bruder G, et al. Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective. Psychol Med. (2015) 45:2959. doi: 10.1017/S0033291715000902
12. Bell MD, Corbata S, Johannesen JK, Fiszdon JM, Wexler BE. Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates? Schizophr Bull. (2013) 39:186–96. doi: 10.1093/schbul/sbt125
13. Comparelli A, Corigliano V, De Carolis A, Mancinelli I, Trovini G, Ottavi G, et al. Emotion recognition impairment is present early and is stable throughout the course of schizophrenia. Schizophr Res. (2013) 143:65–9. doi: 10.1016/j.schres.2012.11.005
14. Bediou B, Asri F, Bruneel J, Krolak-Salmon P, D’Amato T, Saoud M, et al. Emotion recognition and genetic vulnerability to schizophrenia. Br J Psychiatry. (2007) 191:126–30. doi: 10.1192/bjp.bp.106.082889
15. Edwards J, Jackson HJ, Pattison PE. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin Psychol Rev. (2002) 22:789–832. doi: 10.1016/S0272-7358(02)00130-7
16. Bliksted V, Videbech P, Fagerlund B, Frith C. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. Neuropsychology. (2017) 31:209. doi: 10.1037/neu0000309
17. Berndl K, Grüser O-J, Martini M, Remschmidt H. Comparative studies on recognition of faces, mimic and gestures in adolescent and middle-aged schizophrenic patients. Eur Arch Psychiatry Neurol Sci. (1986) 236:123–30. doi: 10.1007/BF00454022
18. Bell M, Bryson G, Lysaker P. Positive and negative affect recognition in schizophrenia: a comparison with substance abuse and normal control subjects. Psychiatry. (1997) 73:73–82. doi: 10.1006/spsy.1997.0011
19. Germain LT, Garrido L, Bruce L, Hooker C. Social anhedonia is associated with neural abnormalities during face emotion processing. Neuroimage. (2011) 58:935–45. doi: 10.1016/j.neuroimage.2011.06.059
20. Gica S, Poyraz BC, Gulec H. Are emotion recognition deficits in patients with schizophrenia states or traits? a 6-month follow-up study indian. J Psychiatry. (2019) 61:45. doi: 10.4103/psychiatry.IndianJournalOfPsychiatry_307_18
21. Glenthoj LB, Albert N, Fagerlund B, Kristensen TD, Wenneberg C, Hjorthøj C. Investigating cognitive and clinical predictors of real-life functioning, functional capacity, and quality of life in individuals at ultra-high risk for psychosis. Schizophr Res. (2019) 210:197–202. doi: 10.1016/j.schres.2018.12.038
22. Glenthoj LB, Kristensen TD, Wenneberg C, Hjorthøj C, Nordentoft M. Investigating cognitive and clinical predictors of real-life functioning, functional capacity, and quality of life in individuals at ultra-high risk for psychosis. Schizophr Bull. (2020) 1:1. doi: 10.1093/schbul/snaa027

AUTHOR CONTRIBUTIONS

MZ, KB, NB, IH, AB, and JK designed and executed the study and conducted the data analyses. MZ wrote the article. TT, SR, EH, and MB collaborated with the design and editing of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

MZ is a participant in the BIH-Charité Junior Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH). In addition, the study was funded through the internal performance-based funding (LoM) of our research group at Charité – Universitätsmedizin Berlin.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.865226/full#supplementary-material
23. Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. *Psychopathology*. (1993) 26:122–6. doi: 10.1159/000284811

24. Andreasen NC. The evolving concept of schizophrenia: from Kraepelin to the present and future. *Schizophr. Res.* (1997) 28:105–9. doi: 10.1016/S0920-9964(97)00112-6

25. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatry Dis Treat.* (2020) 16:519. doi: 10.2147/NDT.S255643

26. Charernboon T. Different subdomains of negative symptoms in clinically stable patients with schizophrenia: determining the nature of their relationships with emotion recognition, theory of mind and neurocognition. *Cogent Psychol.* (2020) 7:1849892. doi: 10.1080/23311908.2020.1849892

27. Bartholomeusz CF, Ganella EP, Labuschagne I, Bousman C, Pantis C. Effects of oxytocin and genetic variants on brain and behaviour: implications for treatment in schizophrenia. *Schizophr. Res.* (2015) 168:614–27. doi: 10.1016/j.schres.2015.06.007

28. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhardt S, Braff DL, et al. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. *Schizophr. Res.* (2007) 90:316–24. doi: 10.1016/j.schres.2006.09.028

29. Mancuso F, Horan WP, Kern RS, Green MF. Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. *Schizophr. Res.* (2011) 125:143–51. doi: 10.1016/j.schres.2010.11.007

30. Ventura J, Subotnik KL, Gitlin MJ, Gretchen-Doorly D, Ered A, Villa KF, et al. Identifying social cognitive impairments and genetic variants on intermediate phenotypes (b-snip) study. *Psychiatry Res.* (2014) 228:316–24. doi: 10.1016/j.psychres.2013.02.014

31. Chang WC, Tang JYM, Hui CLM, Wong GHY, Chan SKW, Lee EHM, et al. The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: a prospective 3-year follow-up study. *Psychiatry Res.* (2013) 209:353–60. doi: 10.1016/j.psychres.2013.02.014

32. Evensen J, Rassberg JL, Baard H, Haahr U, ten Velden Hegelstad W, Joa I, et al. Flat affect and social functioning: a 10 year follow-up study of first episode psychosis patients. *Schizophr. Res.* (2012) 139:99–104. doi: 10.1016/j.schres.2012.04.019

33. Hovington CL, Bodnar M, Joobe R, Malla AK, Lapage M. Identifying persistent negative symptoms in first episode psychosis. *BMC Psychiatry.* (2012) 12:1–11. doi: 10.1186/1471-244X-12-224

34. Bozikas VP, Kosmidis MH, Anezoulaki D, Giannakou M, Karavatos A. Relationship of affect recognition with psychopathology and cognitive performance in schizophrenia. *J Int Neuropsychol Soc.* (2004) 10:549–58. doi: 10.1017/S1355617704004074

35. Catalán A, Gonzalez de Artauza M, Bustamante S, Orga M, A, and et al. Differences in facial emotion recognition between first episode psychosis, borderline personality disorder and healthy controls. *PLoS ONE.* (2011) 6:e160056. doi: 10.1371/journal.pone.0160056

36. Borod JG, Martin CG, Alpert M, Brezgold A, Welkowitz J. Perception of facial emotion in schizophrenic and right brain-damaged patients. *J Nerv Ment Dis.* (1993). doi: 10.1097/00005053-199308000-00004

37. Lewis SF, Garver DL. Treatment and diagnostic subtype in facial affect recognition in schizophrenia. *J Psychiatr Res.* (1995) 29:5–11. doi: 10.1016/0022-3956(94)00033-N

38. Silver H, Shlomo N, Turner T, Gur RC. Perception of happy and sad facial expressions in chronic schizophrenia: evidence for two evaluative systems. *Schizophr. Res.* (2002) 55:171–7. doi: 10.1016/S0920-9964(01)00208-0

39. Bellack AS, Blanchard JL, Mueser KT. Cue availability and affect perception in schizophrenia. *Schizophr Bull.* (1996) 22:535–44. doi: 10.1093/schbul/22.3.535

40. Salem JE, Kring AM, Kerr SL. More evidence for generalized poor performance in facial emotion perception in schizophrenia. *J Abnorm Psychol.* (1996) 105:480. doi: 10.1037/0021-843X.105.3.480

41. Silver H, Shlomo N. Perception of facial emotions in chronic schizophrenia does not correlate with negative symptoms but correlates with cognitive and motor dysfunction. *Schizophr. Res.* (2001) 52:263–73. doi: 10.1016/S0920-9964(00)00099-1

42. Wölwer W, Streit M, Gaebel W, Villemure J, et al. Facial affect recognition in the course of schizophrenia. *Eur Arch Psychiatry Clin Neurosci.* (1996) 246:165–70. doi: 10.1007/BF02189118

43. Mueser KT, Dooran R, Penn DL, Blanchard JL, Bellack AS, Nishith P, et al. Emotion recognition and social competence in chronic schizophrenia. *J Abnorm Psychol.* (1996) 105:271. doi: 10.1037/0021-843X.105.2.271

44. Mueser KT, Penn DL, Blanchard JL, Bellack AS. Affect recognition in schizophrenia: a synthesis of findings across three studies. *Psychiatry.* (1997) 60:301–8. doi: 10.1002/00032747.1997.11024808

45. Sachs G, Steger-Wuchse D, Katschnig H. Facial recognition deficits and cognition in schizophrenia. *Schizophr. Res.* (2004) 68:27–35. doi: 10.1016/S0920-9964(03)00131-2

46. Larei F, Fonteneau B, Mourad H, Raballo A. Basic emotion recognition with psychosis. *Schizophr Bull.* (2014). doi: 10.1097/SMB.0b013e318285189

47. Ekman P, Oster H. Facial expressions of emotion. *Annu Rev Psychol.* (1979) 30:527–54. doi: 10.1146/annurev.ps.30.020179.002523

48. Daniel DG. Issues in selection of instruments to measure negative symptoms. *Schizophr. Res.* (2013) 150:343–5. doi: 10.1016/j.schres.2013.07.005

49. Ahmed AF, Kirkpatrick B, Granholm E, Rowland LM, Barker PB, Gold JM, et al. Two factors, five factors, or both? external validation studies of negative symptom dimensions in schizophrenia. *Schizophr Bull.* (2022) 44:1018. doi: 10.1093/schbul/sbab148
60. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull. (1987) 13:261–76. doi: 10.1093/schbul/13.2.261

61. Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive functioning in clinical trials of schizophrenia. Neurosci Biobehav Rev. (2010) 34:161–77. doi: 10.1016/j.neubiorev.2010.01.012

62. Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. (2014) 24:693–709. doi: 10.1016/j.euroen.2013.10.017

63. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The nimh-matric s consensus statement on negative symptoms. Schizophr Bull. (2006) 32:214–8. doi: 10.1093/schbul/shp053

64. Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, et al. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry. (2016) 3:133–50. doi: 10.1007/s40501-016-0075-8

65. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS).

66. Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive functioning in clinical trials of schizophrenia. Neurosci Biobehav Rev. (2010) 34:161–77. doi: 10.1016/j.neubiorev.2010.01.012

67. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (panss) in schizophrenia. Schizophr Res. (2012) 137:246–50. doi: 10.1016/j.schres.2012.01.031

68. Alphs L, Summerfelt A, Lann H, Muller R. The negative symptom Scale for the Assessment of Negative Symptoms (SANS).

69. Shamay-Tsoory SG, Shur S, Harari H, Levkovitz Y. Neurocognitive basis of impaired empathy in schizophrenia. J Abnorm Psychol. (2003) 54:515–28. doi: 10.1016/S0006-3223(03)00171-9

70. Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, et al. Next-generation negative symptom assessment for clinical trials: validation of the brief negative symptom scale. Schizophr Res. (2012) 142:88–92. doi: 10.1016/j.schres.2012.10.012

71. Vignapiano A, Koenig T, Mucci A, Giordano GM, Amodio A, Altamura A, et al. Disorganization and cognitive impairment in schizophrenia: new insights from electrophysiological findings. Int J Psychophysiol. (2019) 154:99–108. doi: 10.1016/j.ijpsycho.2019.03.008

72. Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficit in schizophrenia: promises and pitfalls of canTab. Eur Psychiatry. (2017) 10:564. doi: 10.3389/fpsyt.2019.01056

73. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The nimh-matric s consensus statement on negative symptoms. Schizophr Bull. (2006) 32:214–8. doi: 10.1093/schbul/shp053

74. Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficit in schizophrenia: promises and pitfalls of canTab. Eur Psychiatry. (2017) 10:564. doi: 10.3389/fpsyt.2019.01056

75. Levaux M-N, Potvin S, Sepehry AA, Sablier J, Mendrek A, Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of cantab. Eur Psychiatry. (2007) 22:104–15. doi: 10.1016/j.eurpsy.2006.11.004

76. Neuechelten KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. (2004) 72:29–39. doi: 10.1016/j.schres.2004.09.007

77. Wright SP. Adjusted P-values for Simultaneous Inference. Biometrics. (1992) 48:1005–13. doi: 10.2307/2532694

78. Wallwork R, Fortgang R, Hashimoto R, Weinerberger D, Dickinson D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res. (2012) 137:246–50. doi: 10.1016/j.schres.2012.01.031
100. Palumbo D, Stanghellini G, Mucci A, Ballerini M, Giordano GM, Lysaker PH, et al. Autism rating scale: a new tool for characterizing the schizophrenia phenotype. *Front Psychiatry.* (2021) 7:62359. doi: 10.3389/fpsyt.2021.62359

101. Bryson G, Bell M, Lysaker P. Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. *Psychiatry Res.* (1997) 71:105–13. doi: 10.1016/S0165-1781(97)00050-4

102. McDonald S, Flanagan S, Rollins J, Kinch J. Tasit: A new clinical tool for assessing social perception after traumatic brain injury. *J Head Trauma Rehabil.* (2003) 18:219–38. doi: 10.1097/00001199-200305000-00001

103. van Elst LT, Fangmeier T, Schaller UM, Hennig O, Kieser M, Koelkebeck K, et al. Faster and scott&eva trainings for adults with high-functioning autism spectrum disorder (Asd): study protocol for a randomized controlled trial. *Trials.* (2021) 22:1–19. doi: 10.1186/s13063-021-05205-9

104. Parpart H, Krankenhagen M, Albantakis L, Henco L, Friess E, Schilbach L. Schematherapie-informiertes, soziales interaktionstraining: interventionsansatz für erwachsene mit hochfunktionalem autismus. *Psychotherapeut.* (2018) 63:235–42. doi: 10.1007/s00278-018-0271-7

105. Averbeck B, Bobin T, Evans S, Shergill S. Emotion recognition and oxytocin in patients with schizophrenia. *Psychol Med.* (2012) 42:259–66. doi: 10.1017/S0033291711001413

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.